Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.

Kosmidis, Paris A

Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. [electronic resource] - Anticancer research Jan 2012 - 175-81 p. digital

Publication Type: Journal Article; Randomized Controlled Trial

1791-7530


Adenocarcinoma--drug therapy
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Neoplasms--drug therapy
Brain Neoplasms--drug therapy
Carcinoma, Large Cell--diagnosis
Carcinoma, Non-Small-Cell Lung--drug therapy
Carcinoma, Squamous Cell--drug therapy
Disease Progression
Female
Follow-Up Studies
Humans
Liver Neoplasms--drug therapy
Lung Neoplasms--drug therapy
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Neoplasm Staging
Paclitaxel--administration & dosage
Small Cell Lung Carcinoma--drug therapy
Survival Rate
Treatment Outcome
Vinblastine--administration & dosage
Vinorelbine